*INVITE* July 13 Virtual NDR with Mgmt Ahead of Phase II PV Data in Aug 2026

Research evidence excerpt

*INVITE* July 13 Virtual NDR with Mgmt Ahead of Phase II PV Data in Aug 2026

Silence Therapeutics PLC (SLN)

Equity Research

July 6, 2026

Company Description

Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in

hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform is

used to target specific disease-associated genes in the liver. Its siRNA molecules harness the body's natural mechanism of RNA interference, and

degrading messenger RNA molecules encode specific targeted disease-associated proteins in a cell. The company develops SLN360, which is in

Phase II clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of nontransfusion-dependent

thalassemia and Phase I/II clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements

with AstraZeneca to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic,

and respiratory diseases; Hansoh Pharmaceutical Group to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform;

and Mallinckrodt Pharma to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated

disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics

plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Company Valuation/Risks

Our price target is DCF-based.